TWA
RARE icon

TCI Wealth Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

TCI Wealth Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2
Closed – – 2472
2022
Q1 		$0 Buy
+2
New +$139 ﹤0.01% 2410
2021
Q2 		– Sell
-54
Closed -$6K – 2431
2021
Q1 		$6K Buy
+54
New +$7.35K ﹤0.01% 1170

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

TCI Wealth Advisors's RARE Position: Q2 2022 in Review

TCI Wealth Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2022, closing a stake of 2 shares.

TCI Wealth Advisors first reported a position in RARE in Q1 2021 and held it in 2 quarters. The position peaked at $6K in Q1 2021. 223 funds tracked by Wall St. Rank hold RARE as of Q2 2022.

  • TCI Wealth Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q2 2022 after selling out during the quarter.
  • TCI Wealth Advisors sold 2 Ultragenyx Pharmaceutical shares in Q2 2022.
  • TCI Wealth Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2021 and held it in 2 quarters.
  • TCI Wealth Advisors's Ultragenyx Pharmaceutical position peaked at $6K in Q1 2021.
  • 223 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2022.

Based on TCI Wealth Advisors's 13F filing for Q2 2022, filed 19 Jul 2022.